NEWS & MEDIA

Amryt Pharma Plc – Director Share Purchases

11 October 2017

Amryt, the biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that, following approval of the Placing, it has received notification that Harry Stratford, Non-Executive Chairman, Joe Wiley, Chief Executive Officer, Rory Nealon, Chief Financial Officer and Chief Operating Officer, Markus Ziener and James Culverwell, Non-Executive Directors of the Company, acquired, in aggregate, 947,731 ordinary shares of 1p each (“Ordinary Shares”). The details of the purchases are as follows:

 

1.            Details

of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Harry Stratford

 

 

2.             

Reason for the notification

 

a)

 

Position / status

 

Non-Executive Chairman

 

b)

 

Initial notification / amendment

 

Initial notification / amendment

Initial notification

 

3.     

      

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Amryt Pharma plc

 

b)

 

Legal entity identifier

 

213800BOS8WAJO2BEQ38

 

4.             

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument,  type of instrument

 

Ordinary shares of £0.01 each

 

Identification code

 

GB00BDD1LS57

 

b)

 

Nature of the transaction

 

Purchase of ordinary shares as part of placing announced on 21 September 2017

 

c)

 

Currency

 

British Pounds

 

d)

 

Price(s) and volume(s)

 

Price(s)

£0.20

Volume(s)

221,592

 
e)  

Aggregated information

·      Aggregated volume

·      Aggregated price

 

150,000

£30,000

 

f)

 

Date of the transaction

 

11 October 2017

 

g)

 

Place of the transaction

 

London Stock Exchange, AIM

 

 

 

1.          

 

Details

of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Joe Wiley

 

2.      

     

Reason for the notification

 

a)

 

Position / status

 

Director

 

b)

 

Initial notification / amendment

 

Initial notification

 

 

3.           

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Amryt Pharma plc

 

b)

 

Legal entity identifier

 

213800BOS8WAJO2BEQ38

 

4.             

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)  

Description of the financial instrument,  type of instrument

Ordinary shares of £0.01 each
 

Identification code

 

GB00BDD1LS57

 

b)

 

Nature of the transaction

 

Purchase of ordinary shares as part of placing announced on 21 September 2017

 

c)

 

Currency

 

British Pounds

 

d)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

£0.20 221,592
 

e)

 

Aggregated information

·      Aggregated volume

·      Aggregated price

 

 

221,592

£44,318.40

 

f)

 

Date of the transaction

 

11 October 2017

 

g)

 

Place of the transaction

 

London Stock Exchange, AIM

 

 

1.            Details

of the person discharging managerial responsibilities / person closely associated

 

 

a)

 

Name

 

Rory Nealon

 

2.           

 

Reason for the notification

 

a)

 

Position / status

 

Director

 

b)

 

Initial notification / amendment

 

Initial notification

 

3.           

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Amryt Pharma plc

 

b)

 

 

Legal entity identifier

 

 

213800BOS8WAJO2BEQ38

 

4.             

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)  

Description of the financial instrument,  type of instrument

 

Ordinary shares of £0.01 each
Identification code GB00BDD1LS57
 

b)

 

Nature of the transaction

 

Purchase of ordinary shares as part of placing announced on 21 September 2017

 

c)

 

Currency

 

British Pounds

 

d)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

£0.20 221,592
e)  

Aggregated information

·      Aggregated volume

·      Aggregated price

 

 

221,592

£44,318.40

 

f)

 

Date of the transaction

 

11 October 2017

 

g)

 

Place of the transaction

 

London Stock Exchange, AIM

 

 

 

1.            Details

of the person discharging managerial responsibilities / person closely associated

 

 

a) Name James Culverwell
 

2.           

 

Reason for the notification

 

a)

 

Position / status

 

Non-Executive Director

 

b)

 

Initial notification / amendment

 

Initial notification

 

3.           

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Amryt Pharma plc

 

b)

 

Legal entity identifier

 

213800BOS8WAJO2BEQ38

4.             

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)  

Description of the financial instrument,  type of instrument

Ordinary shares of £0.01 each
 

Identification code

 

GB00BDD1LS57

 

b)

 

Nature of the transaction

 

Purchase of ordinary shares as part of placing announced on 21 September 2017

 

c)

 

Currency

 

British Pounds

 

d)

 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

£0.20 221,592
e)  

Aggregated information

·      Aggregated volume

·      Aggregated price

 

 

221,592

£44,318.40

 

f)

 

Date of the transaction

 

11 October 2017

 

g)

 

Place of the transaction

 

London Stock Exchange, AIM

 

 

 

1.           

 

Details

of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Marcus Ziener

 

2.           

 

Reason for the notification

 

a)

 

Position / status

 

Non-Executive Director

 

b)

 

Initial notification / amendment

 

Initial notification

 

3.           

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Amryt Pharma plc

 

b)

 

Legal entity identifier

 

213800BOS8WAJO2BEQ38

4.             

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)  

Description of the financial instrument,  type of instrument

Ordinary shares of £0.01 each
 

Identification code

 

GB00BDD1LS57

 

b)

 

Nature of the transaction

 

Purchase of ordinary shares as part of placing announced on 21 September 2017

 

c)

 

Currency British Pounds
d) Price(s) and volume(s)  

Price(s)

 

Volume(s)

£0.20 132,955
e)  

Aggregated information

·      Aggregated volume

·      Aggregated price

 

 

132,955

£26,591

 

f)

 

Date of the transaction

 

11 October 2017

 

g)

 

Place of the transaction

 

London Stock Exchange, AIM

 

 

Enquiries:

Amryt Pharma plc C/o KTZ Communications (details below)
Joe Wiley, CEO

Rory Nealon, CFO/COO

Shore Capital +44 (0) 20 7408 4090
Nomad, Joint Bookrunner and Joint Broker
Edward Mansfield, Mark Percy

 

WG Partners +44 (0) 20 3705 9321
Joint Bookrunner
Nigel Barnes, Nigel Birks, Chris Lee

 

Davy +353 (1) 679 6363
ESM Adviser and Joint Broker
John Frain, Anthony Farrell

 

Stifel +44 (0) 20 7710 7600
Joint Broker
Jonathan Senior, Ben Maddison

 

KTZ Communications +44 (0) 20 3178 6378
Katie Tzouliadis, Irene Bermont-Penn, Emma Pearson

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

c.